Trevi Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Trevi Therapeutics, Inc. (TRVI) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-47.91-29.07-29.15-33.94-32.76-26.05
Depreciation & Amortization0.150.12-0.270.050.050.04
Stock Based Compensation3.592.252.332.542.420.00
Change in Working Capital6.83-3.85-1.231.511.061.95
Change in Accounts Payable1.61-1.050.010.830.420.00
Change in Other Working Capital5.220.950.520.680.640.00
Other Operating Activities-0.910.952.470.290.010.97
Net Cash from Operating Activities-38.26-31.71-28.18-28.95-29.00-23.09
Investing Activities
Capital Expenditures-0.04-0.140.160.00-0.030.01
Purchases of Investments-98.46-9.93-126.220.000.000.00
Sales/Maturities of Investments75.6069.50-107.210.000.000.00
Other Investing Activities1.370.0019.000.000.000.00
Net Cash from Investing Activities-21.5359.43-107.370.00-0.03-0.01
Financing Activities
Debt Repayment-0.13-9.50-5.830.000.000.00
Common Stock Issued61.151.71105.4721.233.1865.10
Other Financing Activities0.46-0.26-5.83-0.45-0.46-1.89
Net Cash from Financing Activities61.48-7.91111.3120.7816.7273.21
Summary
Net Change in Cash1.7019.81-24.24-8.17-12.3150.11
Cash at Beginning of Period32.4012.5936.8345.0057.317.20
Cash at End of Period34.1032.4012.5936.8345.0057.31
Free Cash Flow-38.29-31.85-28.33-28.95-29.03-23.10
Supplemental Disclosures
Interest Paid0.000.33-0.590.600.180.00